CARLSBAD, Calif.–(Organization WIRE)–Jan 20, 2021–
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a scientific-stage biotechnology organization establishing allogeneic mobile therapies for unmet health care wants, currently announced that Brandi Roberts, Chief Financial Officer, presented detect of her resignation on January 15 th, 2021, in get to acknowledge a management situation at a further firm. Ms. Roberts has committed to offering consulting providers to Lineage to guarantee an orderly and smooth changeover to the Company’s new Main Financial Officer. Mr. Brian Culley, Lineage’s Chief Govt Officer, will provide as Interim Chief Money Officer till a new Main Monetary Officer has been appointed. Lineage has commenced a system to discover experienced candidates for the position.
“On behalf of the overall Lineage management workforce and our shareholders, I would like to thank Brandi for her management and numerous contributions through her tenure,” said Brian M. Culley, Lineage CEO. “Brandi performed an integral component in helping Lineage to restructure our functions, reset priorities, and changeover into a top allogeneic mobile transplant therapy corporation. Brandi’s determination aided position Lineage in a powerful placement, operationally and financially, helping us to be properly-positioned for even further progress and reach new milestones in the months and several years forward. We have an understanding of her wish for new problems and wish her the very ideal of success.”
Brandi Roberts included, “I am amazingly very pleased of what the crew has been able to obtain above the earlier two decades. I believe that strongly in the science that supports Lineage’s cell treatment pipeline and will go on to observe the Company’s development in bringing the claims of mobile remedy into scientific truth.”
About Lineage Mobile Therapeutics, Inc.
Lineage Cell Therapeutics is a medical-phase biotechnology business acquiring novel cell therapies for unmet healthcare demands. Lineage’s courses are primarily based on its robust proprietary mobile-based mostly therapy system and related in-property progress and production capabilities. With this system Lineage develops and manufactures specialised, terminally differentiated human cells from its pluripotent and progenitor cell setting up elements. These differentiated cells are created to either swap or assistance cells that are dysfunctional or absent because of to degenerative disorder or traumatic injuries or administered as a suggests of aiding the overall body mount an helpful immune response to most cancers. Lineage’s clinical programs are in marketplaces with billion dollar chances and contain 3 allogeneic (“off-the-shelf”) product or service candidates: (i) OpRegen ®, a retinal pigment epithelium transplant treatment in Period 1/2a advancement for the cure of dry age-associated macular degeneration, a top result in of blindness in the developed environment (ii) OPC1, an oligodendrocyte progenitor cell treatment in Section 1/2a progress for the treatment of acute spinal wire accidents and (iii) VAC, an allogeneic dendritic mobile therapy system for immuno-oncology and infectious disorder, presently in scientific improvement for the cure of non-modest mobile lung most cancers. For more information and facts, remember to take a look at www.lineagecell.com or stick to the Corporation on Twitter @LineageCell.
Forward-Wanting Statements
Lineage cautions you that all statements, other than statements of historical points, contained in this press release, are forward-on the lookout statements. Ahead-on the lookout statements, in some cases, can be determined by terms these as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” project,” “target,” “tend to,” or the adverse variation of these words and phrases and very similar expressions. Such statements include things like, but are not confined to, statements relating to Lineage’s probable expansion. Ahead-looking statements require regarded and unfamiliar dangers, uncertainties and other variables that may perhaps cause Lineage’s precise success, efficiency, or achievements to be materially diverse from upcoming outcomes, efficiency or achievements expressed or implied by the forward-on the lookout statements in this push launch, such as pitfalls and uncertainties inherent in Lineage’s business and other pitfalls in Lineage’s filings with the Securities and Exchange Commission (the SEC). Lineage’s forward-looking statements are based mostly on its present anticipations and involve assumptions that might under no circumstances materialize or might demonstrate to be incorrect. All forward-looking statements are expressly certified in their entirety by these cautionary statements. Even further details pertaining to these and other pitfalls is included less than the heading “Risk Factors” in Lineage’s periodic experiences with the SEC, which include Lineage’s Once-a-year Report on Variety 10-K submitted with the SEC on March 12, 2020 and its other reviews, which are offered from the SEC’s web-site. You are cautioned not to position undue reliance on forward-looking statements, which converse only as of the day on which they had been produced. Lineage undertakes no obligation to update this kind of statements to reflect events that arise or circumstances that exist right after the day on which they were being made, besides as needed by regulation.
Contact: Lineage Mobile Therapeutics, Inc. IR
(442) 287-8963Solebury Trout IR
(646) 378-2949Russo Associates – Media Relations
Nic Johnson or David Schull
Key phrase: UNITED STATES NORTH The us CALIFORNIA
Sector Key word: BIOTECHNOLOGY Hardware Well being Know-how Medical TRIALS
Supply: Lineage Mobile Therapeutics, Inc.
Copyright Business Wire 2021.
PUB: 01/20/2021 04:18 PM/DISC: 01/20/2021 04:18 PM
Copyright Small business Wire 2021.
